Health Care·Pharmaceuticals·$3.4B
Edgewise Therapeutics (EWTX) is a pharmaceutical company focused on developing innovative treatments for serious diseases. With a market cap of $3 billion, it operates within the health care sector, where advancements in drug development are crucial for addressing unmet medical needs.
EPS (Earnings Per Share)
EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.
Revenue Growth
Although revenue estimates are not available, any indication of revenue growth would signal demand for their products and overall business health.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
0Q
EPS Beat Rate
75%
Avg EPS Surprise
+4.00%
Avg Stock Reaction
-1.76%
In Q4 2025, Edgewise reported an EPS of -$0.47, slightly missing expectations. The stock reacted negatively, dropping 1.53% the following day.
Management Promises & Guidance
Investors are cautiously optimistic about Edgewise's upcoming earnings, hoping for a positive surprise in EPS despite a lack of analyst estimates.
Bull Case
If Edgewise can demonstrate better-than-expected EPS and any signs of revenue growth, it could boost investor confidence and drive the stock higher.
Bear Case
Conversely, if the company fails to meet expectations or provides weak guidance, it may lead to further declines in stock price.
EPS (Earnings Per Share)
N/AEPS is a key indicator of the company's profitability and financial health, which investors closely monitor.
Revenue Growth
N/AAlthough revenue estimates are not available, any indication of revenue growth would signal demand for their products and overall business health.
The print will turn on these two things.
Q1
What will the EPS be for Q1-2026?
EPS is a critical measure of profitability, and any significant deviation from expectations could heavily influence stock performance.
Q2
Will there be any updates on revenue generation or product pipeline?
Insights into revenue and product development can provide clarity on the company's growth trajectory and market position.
Why consensus could be wrong
The Street may be underestimating the potential for a positive EPS surprise given the company's recent trend of beating estimates.
Supporting Evidence
75% of the last eight quarters have seen EPS surprises, indicating a pattern of exceeding expectations.
Despite recent misses, the average reaction has been less severe than expected, suggesting resilience.
The lack of analyst estimates may lead to a lower bar for performance, allowing for a potential surprise.
Key Risk
If the EPS comes in better than -$0.30, it could challenge the current cautious outlook.
Pre-commit to what would confirm each case.
This quarter's performance will be closely watched as it could set the tone for the company's future growth and investor confidence.
Bull Confirmed If
An EPS of -$0.30 or better would indicate improved profitability and could validate bullish sentiment.
Bear Confirmed If
An EPS worse than -$0.50 would confirm bearish concerns about the company's financial health.
Implied Move
±N/A
There is no options market data available to gauge investor sentiment ahead of the earnings report.
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Edgewise beats expectations, history suggests the stock could see an average one-day move of around -1.69%, confirming bullish sentiment.
In-Line / Cautious
If results are in line with expectations, the stock may react cautiously, reflecting uncertainty in future guidance.
Miss
Should the company miss expectations, history indicates an average one-day move of -1.99%, which could lead to a negative sentiment shift.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PARAMOUNT SKYDANCE C Class B
May 4, 2026